Related references
Note: Only part of the references are listed.Global prediction of primary liver cancer incidences and mortality in 2040
Chenxi Li et al.
JOURNAL OF HEPATOLOGY (2023)
Exploring Marine as a Rich Source of Bioactive Peptides: Challenges and Opportunities from Marine Pharmacology
Ishtiaq Ahmed et al.
MARINE DRUGS (2022)
Antibody-drug conjugates for multiple myeloma
Annabel McMillan et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2021)
Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma
Mary-Kate Malecek et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2021)
MAPK signaling pathway-targeted marine compounds in cancer therapy
Jiaen Wei et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)
Marine-derived drugs: Recent advances in cancer therapy and immune signaling
Abdullah F. U. H. Saeed et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A
Kris M. White et al.
SCIENCE (2021)
Impact of Parenteral Lipid Emulsion Components on Cholestatic Liver Disease in Neonates
Gregory Guthrie et al.
NUTRIENTS (2021)
Intrathecal pain management with ziconotide: Time for consensus?
Georgios Matis et al.
BRAIN AND BEHAVIOR (2021)
Application of marine natural products in drug research
Wen-Yu Lu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2021)
Lurbinectedin in the treatment of relapsed small cell lung cancer
Javier Baena et al.
FUTURE ONCOLOGY (2021)
Deep Learning in Virtual Screening: Recent Applications and Developments
Talia B. Kimber et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
From Life in the Sea to the Clinic: The Marine Drugs Approved and under Clinical Trial
Emiliano Cappello et al.
LIFE-BASEL (2021)
Whole-Body Pharmacokinetics and Physiologically Based Pharmacokinetic Model for Monomethyl Auristatin E (MMAE)
Hsuan Ping Chang et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Development of Marine-Derived Compounds for Cancer Therapy
Weimin Zuo et al.
MARINE DRUGS (2021)
Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective
Peng Yuan et al.
BREAST CANCER-TARGETS AND THERAPY (2021)
Enriching cancer pharmacology with drugs of marine origin
Paula C. Jimenez et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma
Kirollos S. Hanna
DRUGS (2020)
How has ziconotide impacted non-cancer pain management?
Timothy Deer et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Exploring Topological Pharmacophore Graphs for Scaffold Hopping
Hiroshi Nakano et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2020)
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
Jose Trigo et al.
LANCET ONCOLOGY (2020)
Marine Polyhydroxynaphthoquinone, Echinochrome A: Prevention of Atherosclerotic Inflammation and Probable Molecular Targets
Aleksandr A. Artyukov et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Targeted Therapies and Biomarkers in Small Cell Lung Cancer
Hirokazu Taniguchi et al.
FRONTIERS IN ONCOLOGY (2020)
Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines tor diagnosis, treatment and follow-up
M. Heuser et al.
ANNALS OF ONCOLOGY (2020)
Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US Study) from the Italian Sarcoma Group
Federica Grosso et al.
CANCER (2020)
Marine compounds targeting the PI3K/Akt signaling pathway in cancer therapy
Jiaen Wei et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
A review of computational drug repositioning: strategies, approaches, opportunities, challenges, and directions
Tamer N. Jarada et al.
JOURNAL OF CHEMINFORMATICS (2020)
Marine Compounds and Cancer: Updates 2020
Sergey A. Dyshlovoy et al.
MARINE DRUGS (2020)
Functional Dependency Analysis Identifies Potential Druggable Targets in Acute Myeloid Leukemia
Yujia Zhou et al.
CANCERS (2020)
Insights about clinically approved and Preclinically investigated marine natural products
Mosad A. Ghareeb et al.
CURRENT RESEARCH IN BIOTECHNOLOGY (2020)
Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol
Najdat Bazarbashi et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2020)
Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab
M. L. Amaya et al.
DRUGS OF TODAY (2020)
Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer
Carlos Fernandez-Teruel et al.
CLINICAL PHARMACOKINETICS (2019)
A Scalable Total Synthesis of the Antitumor Agents Et-743 and Lurbinectedin
Weiming He et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2019)
Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
Suzanne Trudel et al.
BLOOD CANCER JOURNAL (2019)
Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine
May Levin et al.
CELL DEATH & DISEASE (2019)
Microalgal Derivatives as Potential Nutraceutical and Food Supplements for Human Health: A Focus on Cancer Prevention and Interception
Christian Galasso et al.
NUTRIENTS (2019)
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma
Ivan Spicka et al.
ANNALS OF HEMATOLOGY (2019)
Therapeutic Cell Protective Role of Histochrome under Oxidative Stress in Human Cardiac Progenitor Cells
Ji Hye Park et al.
MARINE DRUGS (2019)
Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma
Bradley A. McGregor et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Molecular Docking: Shifting Paradigms in Drug Discovery
Luca Pinzi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Animal-derived medicinal products in Russia: Current nomenclature and specific aspects of quality control
Ilya A. Prokopov et al.
JOURNAL OF ETHNOPHARMACOLOGY (2019)
Conotoxins: Chemistry and Biology
Ai-Hua Jin et al.
CHEMICAL REVIEWS (2019)
Integration of core hopping, quantum-mechanics, molecular mechanics coupled binding-energy estimations and dynamic simulations for fragment-based novel therapeutic scaffolds against Helicobacter pylori strains
Chiranjeevi Pasala et al.
COMPUTATIONAL BIOLOGY AND CHEMISTRY (2019)
Dietary Bioactive Fatty Acids as Modulators of Immune Function: Implications on Human Health
Naren Gajenthra Kumar et al.
NUTRIENTS (2019)
Drug repurposing: progress, challenges and recommendations
Sudeep Pushpakom et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Integration of Antibody Array Technology into Drug Discovery and Development
Wei Huang et al.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES (2018)
Do the potential benefits outweigh the risks? An update on the use of ziconotide in clinical practice
E. Backryd
EUROPEAN JOURNAL OF PAIN (2018)
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Jeffrey E. Lancet et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Marine Compounds and Cancer: 2017 Updates
Sergey A. Dyshlovoy et al.
MARINE DRUGS (2018)
Naphthoquinone pigments from sea urchins: chemistry and pharmacology
Alexander N. Shikov et al.
PHYTOCHEMISTRY REVIEWS (2018)
Reverse Screening Methods to Search for the Protein Targets of Chemopreventive Compounds
Hongbin Huang et al.
FRONTIERS IN CHEMISTRY (2018)
Overall survival (OS) results of randomized phase III study (ADMYRE trial) of plitidepsin and dexamethasone (DXM) vs. DXM alone in patients with relapsed/refractory multiple myeloma (RRMM): Evaluation of the crossover impact.
Javier Gomez et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Marine Natural Products in Medicinal Chemistry
Carlos Jimenez
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Application of Molecular Methods in the Identification of Ingredients in Chinese Herbal Medicines
Ke Han et al.
MOLECULES (2018)
CRISPR/Cas9-mediated gene knockout screens and target identification via whole-genome sequencing uncover host genes required for picornavirus infection
Heon Seok Kim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Harnessing off-target effects
Gaye Saginc et al.
NATURE CHEMICAL BIOLOGY (2017)
Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions
C. A. van der Weyden et al.
BLOOD CANCER JOURNAL (2017)
Plitidepsin: design, development, and potential place in therapy
Sara Alonso-Alvarez et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Drugs from the Oceans: Marine Natural Products as Leads for Drug Discovery
Karl-Heinz Altmann
CHIMIA (2017)
Pharmacogenomics of off-target adverse drug reactions
Sarah L. Garon et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
Cristina Belgiovine et al.
BRITISH JOURNAL OF CANCER (2017)
Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates
Xiuxia Sun et al.
BIOCONJUGATE CHEMISTRY (2017)
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia
Philip A. Thompson et al.
BLOOD (2016)
Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives
Erlinda M. Gordon et al.
ADVANCES IN THERAPY (2016)
Approved Antiviral Drugs over the Past 50 Years
Erik De Clercq et al.
CLINICAL MICROBIOLOGY REVIEWS (2016)
Systems pharmacology to predict drug safety in drug development
Mirjam N. Trame et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2016)
The toxicology of heparin reversal with protamine: past, present and future
Emilia Sokolowska et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
Trabectedin for the treatment of soft tissue sarcomas
Rita De Sanctis et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Efficacy of trabectedin for the treatment of liposarcoma
Ritika Zijoo et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM01183 (lurbinectedin), a novel antineoplastic agent, in mouse, rat, dog, Cynomolgus monkey and mini-pig plasma
Tiziana Pernice et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2016)
The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia
James Backes et al.
LIPIDS IN HEALTH AND DISEASE (2016)
Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells
Gema Santamaria Nunez et al.
MOLECULAR CANCER THERAPEUTICS (2016)
CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro
Hinrich P. Hansen et al.
ONCOTARGET (2016)
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
Craig H. Moskowitz et al.
LANCET (2015)
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes
M. Pfeifer et al.
LEUKEMIA (2015)
A perspective on toxicology of Conus venom peptides
Palanisamy Satheesh Kumar et al.
ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE (2015)
Trabectedin, a drug acting on both cancer cells and the tumour microenvironment
M. D'Incalci et al.
BRITISH JOURNAL OF CANCER (2014)
Keyhole limpet haemocyanin - a model antigen for human immunotoxicological studies
Ashwin Swaminathan et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors
Maria Elena Elez et al.
CLINICAL CANCER RESEARCH (2014)
Eribulin Mesylate in the management of metastatic breast cancer and other solid cancers: a drug review
Laura Polastro et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2014)
Clinical potential of elacytarabine in patients with acute myeloid leukemia
Lindsay A. M. Rein et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2014)
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Giovanni Germano et al.
CANCER CELL (2013)
Icosapent ethyl for the treatment of hypertriglyceridemia
Christie M. Ballantyne et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma
Vincent Ribrag et al.
HAEMATOLOGICA (2013)
Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104)
Michela Romano et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Eribulin for Advanced Breast Cancer: A Drug Evaluation
Alaaeldin Shablak
JOURNAL OF BREAST CANCER (2013)
Comparison of the antitumor activity of Trabectedin, Lurbinectedin, Zalypsis and PM00128 in a panel of human cells deficient in transcription/NER repair factors.
Victoria Moneo et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Parenteral nutrition-associated cholestasis: an American Pediatric Surgical Association Outcomes and Clinical Trials Committee systematic review
Shawn J. Rangel et al.
JOURNAL OF PEDIATRIC SURGERY (2012)
Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors
Kyle Jensen et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2012)
Polyanalgesic Consensus Conference 2012: Recommendations for the Management of Pain by Intrathecal (Intraspinal) Drug Delivery: Report of an Interdisciplinary Expert Panel
Timothy R. Deer et al.
NEUROMODULATION (2012)
Anticancer Drug Discovery from the Marine Environment
Candida Nastrucci et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2012)
Balancing repair and tolerance of DNA damage caused by alkylating agents
Dragony Fu et al.
NATURE REVIEWS CANCER (2012)
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Javier Cortes et al.
LANCET (2011)
Tumor-Associated Macrophages as Incessant Builders and Destroyers of the Cancer Stroma
Manuela Liguori et al.
Cancers (2011)
PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity
J. F. M. Leal et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Ziconotide for treatment of severe chronic pain
Achim Schmidtko et al.
LANCET (2010)
Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts
Wah-Seng Lim et al.
LEUKEMIA RESEARCH (2010)
Conopeptide characterization and classifications: An analysis using ConoServer
Quentin Kaas et al.
TOXICON (2010)
The odyssey of marine pharmaceuticals: a current pipeline perspective
Alejandro M. S. Mayer et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2010)
Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain
Howard Howard Smith
Therapeutics and Clinical Risk Management (2010)
The Utility of Omega-3 Fatty Acids in Cardiovascular Disease
Adonis Saremi et al.
AMERICAN JOURNAL OF THERAPEUTICS (2009)
A renaissance in marine pharmacology: From preclinical curiosity to clinical reality
Keith B. Glaser et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Trabectedin: an anticancer drug from the sea
Kristen N. Ganjoo et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)
The effect of deoxyadenosine and cytosine arabinoside on the chromosomes of human leukocytes in vitro
B. A. Kihlman et al.
HEREDITAS (2009)
Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
Linda T. Vahdat et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells
Jie Cai et al.
CANCER RESEARCH (2008)
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743
Daniele Grazziotin Soares et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801
Daniel J. DeAngelo et al.
BLOOD (2007)
Metabolism of trabectedin (ET-743, Yondelis™) in patients with advanced cancer
Jan H. Beumer et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Exploring the sounds of silence: RNAi-mediated gene silencing for target identification and validation
M Chatterjee-Kishore et al.
DRUG DISCOVERY TODAY (2005)
Assessment of drug resistance in acute myeloid leukemia
T Funato et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2004)
Marine natural products and related compounds in clinical and advanced preclinical trials
DJ Newman et al.
JOURNAL OF NATURAL PRODUCTS (2004)
Conus venoms: A rich source of novel ion channel-targeted peptides
H Terlau et al.
PHYSIOLOGICAL REVIEWS (2004)
Mechanisms for T-cell selective cytotoxicity of arabinosylguanine
CO Rodriguez et al.
BLOOD (2003)
Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients
D Wermeling et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Adenosine receptors in the nervous system:: pathophysiological implications
JA Ribeiro et al.
PROGRESS IN NEUROBIOLOGY (2002)
Fludarabine-related pulmonary toxicity - A distinct clinical entity in chronic lymphoproliferative syndromes
DL Helman et al.
CHEST (2002)
Enhancement of cytarabine sensitivity in squamous cell carcinoma cell line transfected with deoxycytidine kinase
H Kojima et al.
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2002)
In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia
CM Galmarini et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair
Y Takebayashi et al.
NATURE MEDICINE (2001)
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action
E Erba et al.
EUROPEAN JOURNAL OF CANCER (2001)
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
KR Rai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
